[
    {
        "outcome_uid": "a7a382d5",
        "clinical_question": "Should patients with MTX-na\u00efve and non-MTX csDMARDs exposed and low disease activity receive MTX monotherapy or an alternative csDMARD monotherapy?",
        "population": "Patients with MTX-na\u00efve and non-MTX csDMARDs exposed RA and low disease activity",
        "intervention": "MTX monotherapy",
        "comparator": "LEF",
        "outcome": "Disease activity (follow up: 4 months; assessed with: ACR 20)",
        "importance": "CRITICAL",
        "related_paper_list": [
            "ade90865"
        ],
        "assessment_results": {
            "GRADE": {
                "Risk of bias": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Inconsistency": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Indirectness": {
                    "result": "SERIOUS",
                    "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a population with moderate to high disease activity."
                },
                "Imprecision": {
                    "result": "VERY_SERIOUS",
                    "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting harm."
                },
                "Other considerations": {
                    "result": "none",
                    "rationales": ""
                },
                "Study design": "Randomized Controlled Trial",
                "Certainty": "VERY LOW",
                "No of participants": {
                    "MTX monotherapy": "88/180 (48.9%)",
                    "LEF": "95/182 (52.2%)"
                },
                "Annotation": {},
                "Effect": {
                    "Relative Effect (95% CI)": "RR 0.94 (0.76 to 1.15)",
                    "Absolute Effect (95% CI)": "31 fewer per 1,000 (from 125 fewer to 78 more)",
                    "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"
                }
            }
        }
    },
    {
        "outcome_uid": "e1285d51",
        "clinical_question": "Should patients with MTX-na\u00efve and non-MTX csDMARDs exposed and low disease activity receive MTX monotherapy or an alternative csDMARD monotherapy?",
        "population": "Patients with MTX-na\u00efve and non-MTX csDMARDs exposed RA and low disease activity",
        "intervention": "MTX monotherapy",
        "comparator": "LEF",
        "outcome": "Disease activity (follow up: 4 months; assessed with: DAS28-ESR (Lower values \u2013 > benefit) (MCID -1.17)",
        "importance": "CRITICAL",
        "related_paper_list": [
            "ad9d3d6b"
        ],
        "assessment_results": {
            "GRADE": {
                "Risk of bias": {
                    "result": "SERIOUS",
                    "rationales": "Downgraded by one level due to serious risk of bias. Lack of blinding of patients, personnel, and outcome assessors."
                },
                "Inconsistency": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Indirectness": {
                    "result": "SERIOUS",
                    "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a population with moderate to high disease activity."
                },
                "Imprecision": {
                    "result": "VERY_SERIOUS",
                    "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting no effect. Small sample size."
                },
                "Other considerations": {
                    "result": "none",
                    "rationales": ""
                },
                "Study design": "Randomized Controlled Trial",
                "Certainty": "VERY LOW",
                "No of participants": {
                    "MTX monotherapy": "21",
                    "LEF": "19"
                },
                "Annotation": {},
                "Effect": {
                    "Relative Effect (95% CI)": "-",
                    "Absolute Effect (95% CI)": "MD 0.67 lower (1.5 lower to 0.16 higher)",
                    "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"
                }
            }
        }
    }
]